EClinical Medicine: Increased risk of inflammatory macular degeneration in patients with bone marrow-boosting tumors.

Epidemiological studies have shown an increased risk of vascular ageing macular degeneration (AMD) in patients with bone marrow-boosting tumors (MPNs).
researchers recently evaluated the incidence of retinal aging and glass warts in MPNs patients using retinal test results, as well as the effects of chronic systemic inflammation on AMD.
200 MPNs patients in the study, divided into three sub-studies.
, color-under-the-eye photo photography was taken on all patients to assess the prevalence of glass warts (compared to three previous large population-based studies).
, in order to assess age-related retinal changes, 150 patients were treated with optically relevant fault imaging and compared with a healthy control group.
, venous blood samples from 63 patients were taken to examine JAK2V617F allegen mutations and neutral granulocyte/lymphocyte ratios (NLR) in patients with glass warts.
compared to three previous population-based studies, the incidence of glass warts in MPNs patients increased significantly, with risk ratios of 5.7, 6.0 and 7.0, respectively.
compared to the healthy control group, the Bruch's membrane-retinal pigment-epithelial complex was thicker in patients with glass warts, but there was no sign of accelerating retinal aging in terms of thinning of the neuro-retina.
, for MPN patients with glass warts, the level of inflammation was higher throughout the body.
study found that bone marrow-building tumors under the retina glass warts aggregation speed up, resulting in early age of macular degeneration, lesions located between the neuroretinas and veins, low-level chronic inflammation on the formation of glass warts and AMD incidence has an important impact.
.